Germany Alzheimer’s Therapeutics Market Analysis

Germany Alzheimer’s Therapeutics Market Executive Summary

Germany alzheimer’s therapeutics market valued at $176 Mn in 2022, projected to reach $309 Mn by 2030 with a 7.3% CAGR.

Alzheimer's is a neurological condition that impairs memory, behavior, and mental health. Usually, it starts slowly, gets worse with time, and makes it harder for the individual to do daily tasks. Nerve cells in Alzheimer's disease die as a result of abnormal brain alterations such as plaque and tangle formation. Alzheimer's disease does not currently have a cure. In contrast, some drugs can help manage symptoms and enhance quality of life. To treat memory and cognitive issues, these medications, which include donepezil, rivastigmine, and memantine, modulate specific neurotransmitters in the brain. Furthermore, non-pharmacological approaches including maintaining a healthy lifestyle, engaging in social and cognitive activities, and fostering a supportive environment might improve overall illness management.

In Germany, there are currently about 1.7 Mn people who suffer from dementia, primarily Alzheimer's disease. By 2070, there could be an increase to 3 Mn, highlighting the significant influence this illness has on the populace. Notable is the age-specific prevalence of dementia, which is approximately 1.91% for people 65-69 and rises to 3.43% for people 80 years of age and older. This pattern of prevalence is consistent with an increasing tendency in Alzheimer's cases, a condition mainly ascribed to the aging of the German population. The changing picture of Alzheimer's prevalence highlights the urgent need for comprehensive policies and preventative actions to address the healthcare issues brought on by an aging population.

In December 2023, BASF and Alector jointly launched a Phase 2b clinical trial for AL001, covering Germany and the US, marking a significant advancement in the treatment of Alzheimer's disease. To slow or stop the progression of the disease, this novel medication directly targets the build-up of Tau protein. It has the potential to be a disease-modifying therapy.

The ongoing Phase 2a trial of ANVS419 by Elan Pharmaceuticals, which was initiated in September 2023 throughout Germany and Belgium, is another significant milestone. This medication is a fresh strategy that shows promise for the treatment of Alzheimer's in the future: it works by inducing the brain's natural processes for eliminating amyloid plaques.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Alzheimer's Disease: Over 1 Mn people in Germany currently suffer from Alzheimer's, placing it among the European countries with the highest burden of the disease. There will be a greater number of people at risk of Alzheimer's as a result of this demographic trend.

Emerging Disease-Modifying Therapies: Research has made significant progress toward ground-breaking discoveries that have opened the door to the development of new medications that aim to address the underlying causes of the illness, raising hopes for the possibility of slowing or even reversing the course of the disease. Promising prospects in the development pipeline in addition to authorized Disease-Modifying Therapies (DMTs) like Leqembi and Aduhelm are notably igniting industry excitement and driving market expansion. These advancements highlight a paradigm-shifting period in the treatment of Alzheimer's disease, indicating a move toward more successful interventions.

Increased Awareness and Early Diagnosis: Due to rising public awareness brought about by proactive initiatives from organizations and advancements in diagnostic technologies, more and more people are seeking therapy for Alzheimer's disease. Thanks to modern diagnostic techniques that allow for early diagnosis, there is a longer window of opportunity for improvement when prospective disease-modifying medications are begun early.

Market Restraints

High Cost of Drugs: The high cost of branded Alzheimer's medications like Exelon and Aricept places a significant financial burden on patients and their families, which may lead to treatment noncompliance, treatment abandonment, or a delayed diagnosis. The lack of reasonably priced generic substitutes further restricts access for those with lower incomes.

Limited Efficacy and Uncertain Long-Term Benefits: The long-term sustainability and effectiveness of existing drugs, like Leqembi and Aduhelm, to delay cognitive deterioration is under question. Hesitancy can be caused by several things, including the lack of a convincing cure or solid proof of improved health.

Lack of Awareness and Stigma: The ongoing social stigma attached to dementia and Alzheimer's disease keeps many people from getting a diagnosis and treatment, especially despite the increasing number of awareness campaigns. This stigma is a major obstacle keeping the market from reaching a larger customer base.

Healthcare Policies and Regulatory Landscape

The Paul-Ehrlich-Institut (PEI) and the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) are in charge of regulating the therapeutic drug market in Germany. Pharmaceutical companies must obtain marketing authorization from these regulatory organizations to introduce therapeutic medications into the German market. This requires the submission of extensive data about safety, efficacy, and quality. Clinical trials are carried out to confirm the drug's safety and efficacy before approval, and regulatory bodies like the BfArM closely examine the trial findings. After a drug is made available to the general public, BfArM oversees post-marketing surveillance, which keeps an eye on its continued safety and effectiveness. Pharmacovigilance operations are carried out to identify, assess, and avoid harmful effects, and the Federal Joint Committee (Gemeinsamer Bundesausschuss, or G-BA) influences reimbursement policies.

Competitive Landscape

Key Players

• Eisai
• Pfizer
• Janssen
• Novartis
• Biogen
• Roche
• Lundbeck
• Otsuka Pharmaceutical
• Teva Pharmaceutical
• Sun Pharmaceutical